SumanMalempatiMD

Pediatric Hematology & Oncology • Portland, OR

Assistant Professor, Pediatrics, Oregon Health and Science University School of Medicine

Join to view full profile

Dr. Malempati is on Doximity

As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.

Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
Connect with colleagues in the same hospital or clinic.
Read the latest clinical news, personalized to your specialty.

See Dr. Malempati's full profile

Already have an account?

Office
3181 Sw Sam Jackson Park Rd
Cdrc-P
Portland, OR 97239
Phone+1 503-494-1543

Fax+1 503-494-0714

Education & Training

Oregon Health & Science University (OHSU Health)Fellowship, Pediatric Hematology/Oncology, 2002 - 2005
University of New Mexico School of MedicineResidency, Pediatrics, 1996 - 1999
Washington University in St. Louis School of MedicineClass of 1996

Certifications & Licensure

OR State Medical License 2005 - 2021

Clinical Trials

IMC-A12 in Treating Young Patients With Relapsed or Refractory Ewing Sarcoma/Peripheral Primitive Neuroectodermal Tumor or Other Solid Tumor Start of enrollment: 2008 Jan 01
Completed
Phase 1
Study of Kidney Tumors in Younger Patients Start of enrollment: 2006 Feb 27
Recruiting
Collecting and Storing Biological Samples From Patients With Ewing Sarcoma Start of enrollment: 2008 Feb 04
Completed
Collecting and Storing Tissue, Blood, and Bone Marrow Samples From Patients With Rhabdomyosarcoma or Other Soft Tissue Sarcoma Start of enrollment: 1999 Mar 15
Completed
Risk-Based Therapy in Treating Younger Patients With Newly Diagnosed Liver Cancer Start of enrollment: 2009 Sep 14
Active, not recruiting
Phase 3
Temozolomide, Cixutumumab, and Combination Chemotherapy in Treating Patients With Metastatic Rhabdomyosarcoma Start of enrollment: 2010 Jan 01
Completed
Phase 2
Combination Chemotherapy in Treating Patients With Non-Metastatic Extracranial Ewing Sarcoma Start of enrollment: 2010 Nov 22
Active, not recruiting
Phase 3
Biomarker in Tumor Tissue Samples From Patients With Rhabdomyosarcoma Start of enrollment: 2011 Jun 01
Completed
Temsirolimus, Dexamethasone, Mitoxantrone Hydrochloride, Vincristine Sulfate, and Pegaspargase in Treating Young Patients With Relapsed Acute Lymphoblastic Leukemia or Non-Hodgkin Lymphoma Start of enrollment: 2011 Sep 01
Completed
Phase 1
Cabozantinib S-Malate in Treating Younger Patients With Recurrent or Refractory Solid Tumors Start of enrollment: 2012 Nov 14
Completed
Phase 1
MORAb-004 in Treating Young Patients With Recurrent or Refractory Solid Tumors or Lymphoma Start of enrollment: 2013 Nov 01
Completed
Phase 1
VEGF Receptor Tyrosine Kinase Inhibitor Axitinib in Children With Recurrent or Refractory Solid Tumors Start of enrollment: 2014 Sep 01
Completed
Phase 1
Risk-Based Therapy in Treating Younger Patients With Newly Diagnosed Liver Cancer Start of enrollment: 2009 Sep 01
A Study of Ramucirumab (LY3009806) in Children With Refractory Solid Tumors Start of enrollment: 2015 Dec 11
Completed
Phase 1
Entinostat in Treating Pediatric Patients With Recurrent or Refractory Solid Tumors Start of enrollment: 2017 Jan 06
Completed
Phase 1
Join now to see all

Publications & Presentations

PubMed

122 citations
Phase 2 trial of cixutumumab in children, adolescents, and young adults with refractory solid tumors: a report from the Children's Oncology Group.
Brenda J. Weigel, Suman Malempati, Joel M. Reid, Stephan D. Voss, Steven Y. Cho
Pediatric Blood & Cancer. 2014-03-01
140 citations
Phase I/II Trial and Pharmacokinetic Study of Cixutumumab in Pediatric Patients With Refractory Solid Tumors and Ewing Sarcoma: A Report From the Children's Oncology G...
Suman Malempati, Brenda J. Weigel, Ashish M. Ingle, Charlotte H. Ahern, Julie M. Carroll
Journal of Clinical Oncology. 2012-01-20
48 citations
Phase II trial of the glycoprotein non-metastatic B-targeted antibody–drug conjugate, glembatumumab vedotin (CDX-011), in recurrent osteosarcoma AOST1521: A report fro...
Lisa M. Kopp, Suman Malempati, Mark Krailo, Yun Gao, Allen Buxton
European Journal of Cancer. 2019-11-01

Lectures

ADVL1513: Results of a phase 1 trial of entinostat, an oral histone deacetylase inhibitor, in pediatric patients with recurrent or refractory solid tumors.
2018 ASCO Annual Meeting - Chicago, Illinois - 06/2/2018

Press Mentions

Emory’s Year in ReviewDecember 16th, 2021
A Career of Service, from Doctor to Social Justice LawyerMay 7th, 2021
New Approach to Drug Resistance in Aggressive Childhood Cancer DiscoveredMarch 31st, 2011